• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Eli Lilly’s tirzepatide injection results could trigger another bull run: Here’s why

by August 1, 2024
written by August 1, 2024

Eli Lilly and Company (NYSE: LLY) recently announced promising results from its SUMMIT phase 3 trials, focusing on the efficacy of the tirzepatide injection.

The positive findings have sparked investor interest, driving the stock up by 3% today.

These results are not only significant for Eli Lilly but also hold potential for millions of patients suffering from heart failure with preserved ejection fraction (HFpEF) and obesity.

Promising trial results

The SUMMIT phase 3 trial results revealed that tirzepatide reduced the risk of heart failure outcomes by 38% compared to a placebo. Additionally, all key secondary endpoints were successfully met, including:

It reduced the risk of heart failure outcomes by 38% compared to placebo.

All l key secondary endpoints were met successfully. These included exercise capacity, mean body weight reduction from baseline at 52 weeks, and reduction in the inflammation marker high-sensitivity C-reactive protein.

For the efficacy estimand, it led to a 15.7% weight reduction compared to 2.2% for placebo.

For the treatment regimen estimand, it led to a 13.9% reduction in body weight compared to 2.2% for placebo.

Why is this result significant?

The result carries weight because HFpEF (heart failure with preserved ejection fraction) accounts for 50% of all heart failure cases. In the US, 60% of those also suffer from obesity.

It is a condition where the left pumping chamber of the heart becomes stiff and is unable to fill normally. Thanks to tirzepatide, this problem can finally be addressed.

The company will now submit the SUMMIT study findings to the FDA and hope for a positive response from them. If the drug is approved, tirzepatide could become the cornerstone of Eli Lilly’s portfolio and substantially boost revenue.

CEO says shortage of tirzepatide should end soon

CEO David Ricks had more good news for the investors today as he claimed the shortage of tirzepatide should end soon. He made this revelation during an interview with Bloomberg.

Some doses of LLY’s weight loss drugs Zepbound and Mounjaro have been on FDA’s shortage list for some time now. In fact, Mounjaro is on that list since since 2022.

The company had initially stated in April that it expects the supply to remain tight. However, the CEO’s comments have increased investor confidence and hopes.

What does the chart say?

LLY stock has been on a downslide recently as the US market corrects across the board. The announcement of the drug trial comes at a time when the stock was about to test a key support level as shown in the chart below.

The trendline that started over a year ago was about to be approached but the stock price never reached there. Traders will probably still wait for a retesting of that line but investors, on the back of above positive developments will hope that the retesting isn’t needed and the stock can continue its upward journey.

As the market tumbles today, investors will find comfort in the fact that LLY stock is still up 3%. Only time will tell if that’s temporary though.

The post Eli Lilly’s tirzepatide injection results could trigger another bull run: Here’s why appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
CleanSpark expands in Wyoming, overtakes Riot as second-largest Bitcoin miner in US
next post
Riot Platforms stock has a 71% upside: analyst

related articles

Asian markets open: Nikkei, Hang Seng fall on...

June 12, 2025

Aluminum and steel tariffs spark rise in secondary...

June 12, 2025

Airbus sees aviation boom ahead, global fleet to...

June 12, 2025

US-China trade talks and Washington’s decade-long effort to...

June 12, 2025

Europe markets open: Stoxx 600 dips as UK...

June 12, 2025

UK GDP falls by 0.3% in April as...

June 12, 2025

Gordon Brothers buys Poundland; pledges £80 mn for...

June 12, 2025

Air India plane crash: London-bound flight with 242...

June 12, 2025

Air India plane crash live update: Indian President...

June 12, 2025

Copper remains supported for now even as China...

June 12, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Where Vance and Walz favorability ratings stand 60 days to Election Day

    September 5, 2024
  • Wolfe Research upgrades First Industrial Realty Trust: Can it reach $64?

    August 14, 2024
  • DWAC Stock Seems at a Standstill. What Is the Forecast? 

    August 2, 2024
  • Here is who is vying for power in Syria after the fall of Bashar al-Assad

    December 9, 2024
  • Dems ‘deliberately obfuscating’ truth about ‘big, beautiful bill’ with this claim: Watchdog

    June 15, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (5,602)
  • Investing (634)
  • Stock (867)

Latest Posts

  • Elon Musk protests to target lawmakers, Tesla dealerships as progressives decry ‘extremist cuts’

    February 18, 2025
  • AMD investors anticipate key updates on new GPU line ahead of Q2 earnings

    July 30, 2024
  • ‘Lying to the nation’: Trump orbit slams Biden for taking credit for ceasefire deal

    January 16, 2025

Recent Posts

  • Vance says Russia’s demands are too high, but there’s still a path to ‘durable peace’ with Ukraine

    May 7, 2025
  • Canada stares down consequences of Trump tariff war: Job losses, grocery price hikes, possible recession

    April 2, 2025
  • Harris campaign silent on House bill banning contracts with ‘Chinese military company’ amid Walz ties

    September 12, 2024

Editor’s Pick

  • Trump calls Springsteen ‘highly overrated’ after rocker labels him ‘treasonous’ overseas

    May 16, 2025
  • Ex-Biden advisor Mike Donilon sits down with House investigators in autopen probe

    July 31, 2025
  • Stocks fall as comeback rally falters; Dow lower by 100 points

    August 8, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock